StreetInsider.com News Articles

Form 4 XBiotech Inc. For: Oct 26 Filed by: Simard Jan-Paul

Wed, 28 Oct 2026 15:32:00 -0500

si-local-file:///var/storage/secattach/20261028/27248795.html

Form 3 XBiotech Inc. For: Oct 23 Filed by: Simard Jan-Paul

Wed, 28 Oct 2026 15:30:00 -0500

si-local-file:///var/storage/secattach/20261028/27248753.html

Form 4 XBiotech Inc. For: Oct 26 Filed by: SIMARD JOHN

Wed, 28 Oct 2026 14:37:00 -0500

si-local-file:///var/storage/secattach/20261028/27248468.html

Form 8-K XBiotech Inc. For: Oct 23

Mon, 26 Oct 2026 09:39:00 -0500

si-local-file:///var/storage/secattach/20261026/27231910.html

XBiotech names co-CEOs as Simard joins Shivaswamy in leadership

Fri, 23 Oct 2026 09:18:22 -0500

XBiotech Inc. (NASDAQ: XBIT) announced that its board of directors has elected Jan-Paul Simard as Co-Chief Executive Officer, effective Oct. 23, 2026, to serve alongside Dr. Sushma Shivaswamy, who retains her CEO role.

Dr. Shivaswamy has been with the Austin, Texas-based biosciences company for 17 years, holding roles including Senior Scientist, Director, and Vice President of Research & Development before becoming Chief Scientific Officer in 2017. She was named interim CEO in December 2025 following the retirement of founder John Simard.

Jan-Paul Simard joined XBiotech in 2012 as an R&D assistant and moved to the clinical development team in 2020, where he

XBiotech names co-CEOs as Simard joins Shivaswamy in leadership

Fri, 23 Oct 2026 09:18:22 -0500

Jan-Paul Simard joined XBiotech in 2012 as an R&D assistant and moved to the clinical development team in 2020, where he

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

Fri, 23 Oct 2026 09:17:00 -0500

AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.

“On behalf of the Board of Directors, we are excited to announce Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers,” said Director Tevi Troy. “Their complementary skill sets, scientific acumen, and shared commitment to our mission position XBiotech to fully realize the potential of our True-Human antibody therapies.”

Dr. Shivaswamy has been with XBiotech for 17

XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

Fri, 23 Oct 2026 09:17:00 -0500

Dr. Shivaswamy has been with XBiotech for 17

XBiotech's cancer drug meets survival threshold in phase II trial

Mon, 19 Oct 2026 09:01:12 -0500

XBiotech Inc. (NASDAQ: XBIT) announced positive final efficacy results from the Phase II portion of the TASKIN clinical trial, an investigator-sponsored study evaluating its anti-IL-1α monoclonal antibody vilamakitug (Natrunix™, XB2001) in patients with refractory metastatic colorectal cancer (mCRC).

The study, funded by the French National Cancer Institute (INCa) and coordinated by the Centre Georges-François Leclerc (CGFL) in Dijon, France, met its pre-specified primary efficacy success criterion. At the 12-month landmark analysis, 49 of 80 evaluable patients (61.3%) in the vilamakitug arm were alive, exceeding the protocol-defined threshold of 42 or more surviving patients. In the control arm, 44 of 79 evaluable

XBiotech's cancer drug meets survival threshold in phase II trial

Mon, 19 Oct 2026 09:01:12 -0500

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

Mon, 19 Oct 2026 09:00:00 -0500

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.

Exploratory Subgroup analysis reveals significant survival benefit in right-sided tumors.

AUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by the French National Cancer Institute (INCa) and coordinated by investigators at the Centre Georges-François Leclerc (CGFL) in Dijon, France—evaluated the addition of XBiotech’s anti-IL-1α monoclonal antibody, XB2001 (Natrunix™, vilamakitug), to standard-of-care

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

Mon, 19 Oct 2026 09:00:00 -0500

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.

Exploratory Subgroup analysis reveals significant survival benefit in right-sided tumors.

Form ARS XBiotech Inc. For: Oct 02

Fri, 02 Oct 2026 11:14:00 -0500

si-local-file:///var/storage/secattach/20261002/27140156.html

Form DEF 14A XBiotech Inc. For: Nov 24

Fri, 02 Oct 2026 11:13:00 -0500

si-local-file:///var/storage/secattach/20261002/27140150.html

Form 10-Q XBiotech Inc. For: Jun 30

Thu, 13 Aug 2026 11:27:00 -0500

si-local-file:///var/storage/secattach/20260813/26918620.html

Form 10-Q XBiotech Inc. For: Jun 30

Thu, 13 Aug 2026 11:27:00 -0500

si-local-file:///var/storage/secattach/20260813/26918620.html

XBiotech starts phase II trial of vilamakitug for axial spondyloarthritis

Mon, 15 Jun 2026 09:01:05 -0500

XBiotech Inc. (NASDAQ: XBIT) announced its Investigational New Drug application for a Phase II clinical trial evaluating vilamakitug in patients with active axial spondyloarthritis has completed the FDA's 30-day review period without clinical hold. The company can now proceed with patient enrollment in the United States.

The V-SPINE study will evaluate 400 mg of vilamakitug administered as 16 weekly subcutaneous injections versus placebo in 150 adult participants with active axial spondyloarthritis. The primary endpoint measures the proportion of participants achieving an ASAS40 response at Week 16. The study includes a 12-week open-label extension where all participants receive vilamakitug.

Marina Magrey, M.D., serves

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

Mon, 15 Jun 2026 09:00:00 -0500

IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment

AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Investigational New Drug (IND) application for V-SPINE (PT064), a Phase II, double-blind, placebo-controlled, randomized study evaluating the efficacy and safety of vilamakitug in participants with active axial spondyloarthritis, has successfully completed the U.S. Food and Drug Administration’s (FDA) 30-day review period without a clinical hold. The study is now authorized to proceed with patient enrollment in the United States, marking the

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

Mon, 15 Jun 2026 09:00:00 -0500

IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment

Form 10-Q XBiotech Inc. For: Mar 31

Thu, 14 May 2026 14:44:00 -0500

si-local-file:///var/storage/secattach/20260514/26493778.html

Form 10-Q XBiotech Inc. For: Mar 31

Thu, 14 May 2026 14:44:00 -0500

si-local-file:///var/storage/secattach/20260514/26493778.html

Form 10-K/A XBiotech Inc. For: Dec 31

Wed, 29 Apr 2026 13:02:00 -0500

si-local-file:///var/storage/secattach/20260429/26392146.html

Form 10-K/A XBiotech Inc. For: Dec 31

Wed, 29 Apr 2026 13:02:00 -0500

si-local-file:///var/storage/secattach/20260429/26392146.html

Form 10-K XBiotech Inc. For: Dec 31

Fri, 13 Mar 2026 14:34:00 -0500

si-local-file:///var/storage/secattach/20260313/26158885.html

Form 10-K XBiotech Inc. For: Dec 31

Fri, 13 Mar 2026 14:34:00 -0500

si-local-file:///var/storage/secattach/20260313/26158885.html